This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Esperion Therapeutics (ESPR) Down 24% in a Week: Here's Why
by Zacks Equity Research
Shares of Esperion Therapeutics (ESPR) fell last week as the company's cardiovascular outcome CLEAR study results failed to meet investor expectations.
Pharma Stock Roundup: LLY's Alzheimer's Study Setback, FDA Updates for SNY, MRK
by Kinjel Shah
FDA accepts Sanofi's (SNY) Dupixent sBLA. Lilly's (LLY) solanezumab fails to prevent Alzheimer's in a study.
Zacks Industry Outlook Highlights J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi
by Zacks Equity Research
J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi have been highlighted in this Industry Outlook article.
5 Large Drug Stocks to Watch as Sector Picks Up in 2023
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sanofi (SNY) are worth retaining in your portfolio.
Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review
by Zacks Equity Research
Sanofi's (SNY) sBLA seeking label expansion of drug Dupixent for chronic spontaneous urticaria accepted by the FDA
Sanofi (SNY) Stock Moves -0.38%: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed at $47.55 in the latest trading session, marking a -0.38% move from the prior day.
Zacks.com featured highlights Sanofi, SK Telecom, PBF Energy, Arrow Electronics and Novartis
by Zacks Equity Research
Sanofi, SK Telecom, PBF Energy, Arrow Electronics and Novartis have been highlighted in this Screen of The Week article.
AstraZeneca (AZN) Enhertu Betters Outcomes in Multi-Tumor Study
by Zacks Equity Research
AstraZeneca (AZN) and Daiichi Sankyo' Enhertu met the pre-specified criteria for objective response rate and duration of response in the DESTINY-PanTumor02 phase II study.
These 5 Price-to-Sales Stocks Can Be Rewarding Investments
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like SNY, SKM, PBF, ARW and NVS hold promise.
Top Stock Reports for Cisco Systems, T-Mobile US & Stryker
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc. (CSCO), T-Mobile US, Inc. (TMUS) and Stryker Corporation (SYK).
BioMarin (BMRN) Q4 Earnings Miss, Sales Beat, Stock Down
by Zacks Equity Research
BioMarin (BMRN) reports mixed Q4 results as it misses estimates for earnings but beats the same for sales. Its 2023 sales guidance falls short slightly
Denali (DNLI) Q4 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Denali (DNLI) reports better-than-expected results for the fourth quarter and full-year 2022, as it beats both earnings and revenue estimates.
Zacks.com featured highlights JinkoSolar, UFP Industries, ASE Technology, Concrete Pumping Holdings and Sanofi
by Zacks Equity Research
JinkoSolar, UFP Industries, ASE Technology, Concrete Pumping Holdings and Sanofi have been highlighted in this Screen of The Week article.
5 Stocks With Amazingly Low EV-to-EBITDA Ratios to Snap Up
by Anindya Barman
We have screened value stocks JKS, UFPI, ASX, BBCP and SNY based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.
Pharma Stock Roundup: FDA Updates for SNY, PFE & Others, EU Nod to AZN Cancer Combo
by Kinjel Shah
FDA approves Sanofi's (SNY) Altuviiio and grants a priority tag to Pfizer's (PFE) regulatory applications for pipeline candidates.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
SNY vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SNY vs. NVO: Which Stock Is the Better Value Option?
Pfizer (PFE) Eczema Drug Cibinqo Gets FDA Nod for Adolescents
by Zacks Equity Research
The FDA approval for Pfizer's (PFE) Cibinqo to treat moderate-to-severe atopic dermatitis in adolescents was based on data from the phase III study, JADE TEEN.
AstraZeneca (AZN) Q4 Earnings Beat, Sales Hurt by COVID Jab
by Zacks Equity Research
AstraZeneca (AZN) beats fourth-quarter estimates for earnings while missing the same for sales.
New Strong Buy Stocks for February 7th
by Zacks Equity Research
DLAKY, UBS, SNY, EVR and TME have been added to the Zacks Rank #1 (Strong Buy) List on February 7, 2022.
Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology
by Zacks Equity Research
Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.
Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline
by Zacks Equity Research
Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.
Sanofi (SNY) Q4 Earnings Miss Estimates, Vaccine Sales Weak
by Zacks Equity Research
Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. Higher sales of Dupixent and other specialty medicines were offset by a decline in vaccine sales.
Pharma Stock Roundup: MRK, LLY, PFE Q4 Results, J&J's Loss in Talc Lawsuits
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Eli Lilly (LLY) and others report fourth-quarter results. An appeals court dismisses J&J's (JNJ) bankruptcy filing related to its talc lawsuits.
Bristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact Sales
by Zacks Equity Research
Bristol-Myers' (BMY) fourth-quarter 2022 earnings beat estimates, while sales declined year over year due to generic erosion for oncology drug Revlimid.